Pfizer hikes full-year outlook as Q2 results top estimates; shares up
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Pfizer Reports Strong Second-Quarter 2024 Results And Raises 2024 Guidance
July 30, 2024 6:45 AM EDTSecond-Quarter Performance Driven by Focused Commercial Execution Raises Full-Year 2024 Revenue Guidance(1) to a Range of $59.5 to $62.5 Billion and Raises Adjusted(2) Diluted EPS Guidance to a Range of $2.45 to $2.65 Launched Manufacturing Optimization Program with Anticipated Cost Savings of Approximately $1.5 Billion by the End of 2027 Second-Quarter 2024 Revenues of $13.3 Billion Revenues Grew 3% Operationally Year-over-Year Despite Anticipated Decline in COVID Revenues Excluding Contributions from Comirnaty(3) and Paxlovid, Revenues Grew 14% Operationally Second-Quarter 2024 Reported(4) Diluted EPS of $0.01 and Adjusted(2) Diluted EPS of $0.60 Includes $1.3 Billion of One-Time Costs for... More
